ArticleScientific reports2025
Identification of diagnostic biomarkers and dissecting immune microenvironment with crosstalk genes in the POAG and COVID-19 nexus.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An underlying association between primary open-angle glaucoma (POAG) and COVID-19 has been hypothesized, but the causal link and shared mechanisms remain unclear. This study integrates epidemiological and bioinformatics approaches to investigate their relationship, aiming to identify common molecular pathways and validate clinical correlations. Epidemiological data from 3,015 participants in the CHARLS database were analyzed using multivariate logistic regression and Cox proportional hazards models to assess the association between COVID-19 and POAG, with stratification by gender, smoking status, and alcohol consumption. Concurrently, gene expression datasets from GEO (POAG: GSE27276; COVID-19: GSE171110, GSE152418) were used to identify 57 crosstalk genes (CGs) via differential expression analysis. Machine learning algorithms (LASSO, SVM-RFE, Random Forest) were applied to screen POAG diagnostic biomarkers from CGs, followed by construction of transcription factor (TF)-microRNA (miRNA)-protein-compound regulatory networks and consensus clustering to characterize COVID-19 immune microenvironment subtypes. Epidemiological analyses revealed that COVID-19 was an independent risk factor for POAG, with adjusted odds ratios (ORs) of 12.775-15.688 and hazard ratios (HRs) of 4.893-5.060 (all P < 0.001), with stronger associations in males (OR = 15.054, HR = 5.645) and smokers (OR = 29.828, HR = 9.323). HDL levels were significantly higher in POAG patients (P = 0.028), while vb001_s1 positivity was negatively associated with POAG (P < 0.001). Bioinformatics identified CGs enriched in inflammatory response, oxidative stress, and hypoxia pathways. Five potential biomarkers (CA12, ECRG4, CEBPD, HBB, HBA2) showed high diagnostic efficacy (AUC > 0.9) but limited specificity (expressed in uveitis and diabetic retinopathy). COVID-19 patients were stratified into three clusters, with Cluster B exhibiting hyperactive immune microenvironments characterized by elevated HLA class I/II and immune checkpoint genes (CTLA4, PDCD1LG2) in antigen-presenting cells and T cells. This study provides epidemiological and molecular evidence linking POAG to COVID-19, highlighting inflammation and immune dysregulation as shared mechanisms. Gender and smoking modify this association, warranting targeted POAG screening in male COVID-19 survivors and smokers. While identified biomarkers require specificity improvement, findings underscore the need for mechanistic studies (e.g., ACE2-mediated ocular injury, T-cell neuroinflammation) to validate causality and inform clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.